UBS Group
ASBPW

UBS Group’s Aspire Biopharma Warrant ASBPW Stock Holding History

UBS Group’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-453
Closed -$23 – 10031
2023
Q3 		$23 Buy
+453
New +$37 ﹤0.01% 9104
2022
Q4 		– Sell
-5
Closed – – 11244
2022
Q3 		$0 Sell
5
-24,995
-100% -$3.64K ﹤0.01% 11057
2022
Q2 		$4K Buy
+25,000
New +$5.44K ﹤0.01% 9157

Other funds holding ASBPW

AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

UBS Group's ASBPW Position: Q4 2023 in Review

UBS Group sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2023, closing a stake of 453 shares — an estimated $23 sold.

UBS Group first reported a position in ASBPW in Q2 2022 and held it in 3 quarters. The position peaked at $4K in Q2 2022. 35 funds tracked by Wall St. Rank hold ASBPW as of Q4 2023.

  • UBS Group reported no remaining Aspire Biopharma Warrant position as of Q4 2023 after selling out during the quarter.
  • UBS Group sold 453 Aspire Biopharma Warrant shares in Q4 2023, an estimated $23.
  • UBS Group first reported a position in Aspire Biopharma Warrant in Q2 2022 and held it in 3 quarters.
  • UBS Group's Aspire Biopharma Warrant position peaked at $4K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2023.

Based on UBS Group's 13F filing for Q4 2023, filed 9 Feb 2024.